A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Completed · Phase 2

Conditions studied: Metastatic Pancreatic Cancer

In brief

The purpose of this clinical research study is to learn if ixabepilone plus cetuximab improves survival when given as 1st line chemotherapy in subjects with metastatic pancreatic cancer compared to historical data. The safety of this combination treatment will also be studied.

Key facts

Study ID

NCT00383149

Run by

R-Pharm

People needed

58

Starts

2007-01-01

Expected to finish

2009-06-01

Last updated by the study team

2016-03-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic or cytologic diagnosis of pancreatic adenocarcinoma (locally advanced disease that is not surgically resectable, or distant metastatic disease)
• Participants must have measurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) guidelines
• Participants must not have received prior chemotherapy, immunotherapy or chemoradiotherapy for advanced pancreas cancer
• Karnofsky performance status (KPS) of 70-100
• Adequate hematologic, hepatic and renal function

Where it is running

• Georgetn Univ Lombardi Can Ctr — Washington D.C., District of Columbia, United States
• Mayo Clinic Jacksonville — Jacksonville, Florida, United States
• University Of Miami — Miami, Florida, United States
• University Of Michigan — Ann Arbor, Michigan, United States
• Wayne State University — Detroit, Michigan, United States
• Ellis Fischel Cancer Center — Columbia, Missouri, United States
• Cancer Centers Of The Carolinas — Greenville, South Carolina, United States
• Seattle Cancer Care Alliance — Seattle, Washington, United States
• West Virginia University — Morgantown, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.